The global Vasomotor Symptoms of Menopause Treatment market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Vasomotor Symptoms of Menopause Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Vasomotor Symptoms of Menopause Treatment.

Report Scope

The Vasomotor Symptoms of Menopause Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Vasomotor Symptoms of Menopause Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Vasomotor Symptoms of Menopause Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Vasomotor Symptoms of Menopause Treatment Market Report

Report Metric	Details
Report Name	Vasomotor Symptoms of Menopause Treatment Market
CAGR	5%
Segment by Type	Estetrol Fezolinetant FP-101 HBN-2 Others
Segment by Application	Hospital Homecare Clinic
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Amgen Inc., EndoCeutics, Inc., Euroscreen S.A., MenoGeniX, Inc., Mithra Pharmaceuticals S.A., Pherin Pharmaceuticals, Inc., Pivot Pharmaceuticals Inc, Radius Health, Inc., TherapeuticsMD, Inc.
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Vasomotor Symptoms of Menopause Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Vasomotor Symptoms of Menopause Treatment Market report?

Ans: The main players in the Vasomotor Symptoms of Menopause Treatment Market are Amgen Inc., EndoCeutics, Inc., Euroscreen S.A., MenoGeniX, Inc., Mithra Pharmaceuticals S.A., Pherin Pharmaceuticals, Inc., Pivot Pharmaceuticals Inc, Radius Health, Inc., TherapeuticsMD, Inc.

What are the Application segmentation covered in the Vasomotor Symptoms of Menopause Treatment Market report?

Ans: The Applications covered in the Vasomotor Symptoms of Menopause Treatment Market report are Hospital, Homecare, Clinic

What are the Type segmentation covered in the Vasomotor Symptoms of Menopause Treatment Market report?

Ans: The Types covered in the Vasomotor Symptoms of Menopause Treatment Market report are Estetrol, Fezolinetant, FP-101, HBN-2, Others

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Vasomotor Symptoms of Menopause Treatment Market Size Growth Rate by Type: 2019 VS 2023 VS 2030

1.2.2 Estetrol

1.2.3 Fezolinetant

1.2.4 FP-101

1.2.5 HBN-2

1.2.6 Others

1.3 Market by Application

1.3.1 Global Vasomotor Symptoms of Menopause Treatment Market Growth by Application: 2019 VS 2023 VS 2030

1.3.2 Hospital

1.3.3 Homecare

1.3.4 Clinic

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2 Global Growth Trends

2.1 Global Vasomotor Symptoms of Menopause Treatment Market Perspective (2019-2030)

2.2 Vasomotor Symptoms of Menopause Treatment Growth Trends by Region

2.2.1 Global Vasomotor Symptoms of Menopause Treatment Market Size by Region: 2019 VS 2023 VS 2030

2.2.2 Vasomotor Symptoms of Menopause Treatment Historic Market Size by Region (2019-2024)

2.2.3 Vasomotor Symptoms of Menopause Treatment Forecasted Market Size by Region (2025-2030)

2.3 Vasomotor Symptoms of Menopause Treatment Market Dynamics

2.3.1 Vasomotor Symptoms of Menopause Treatment Industry Trends

2.3.2 Vasomotor Symptoms of Menopause Treatment Market Drivers

2.3.3 Vasomotor Symptoms of Menopause Treatment Market Challenges

2.3.4 Vasomotor Symptoms of Menopause Treatment Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Vasomotor Symptoms of Menopause Treatment Players by Revenue

3.1.1 Global Top Vasomotor Symptoms of Menopause Treatment Players by Revenue (2019-2024)

3.1.2 Global Vasomotor Symptoms of Menopause Treatment Revenue Market Share by Players (2019-2024)

3.2 Global Vasomotor Symptoms of Menopause Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Vasomotor Symptoms of Menopause Treatment Revenue

3.4 Global Vasomotor Symptoms of Menopause Treatment Market Concentration Ratio

3.4.1 Global Vasomotor Symptoms of Menopause Treatment Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Vasomotor Symptoms of Menopause Treatment Revenue in 2023

3.5 Vasomotor Symptoms of Menopause Treatment Key Players Head office and Area Served

3.6 Key Players Vasomotor Symptoms of Menopause Treatment Product Solution and Service

3.7 Date of Enter into Vasomotor Symptoms of Menopause Treatment Market

3.8 Mergers & Acquisitions, Expansion Plans

4 Vasomotor Symptoms of Menopause Treatment Breakdown Data by Type

4.1 Global Vasomotor Symptoms of Menopause Treatment Historic Market Size by Type (2019-2024)

4.2 Global Vasomotor Symptoms of Menopause Treatment Forecasted Market Size by Type (2025-2030)

5 Vasomotor Symptoms of Menopause Treatment Breakdown Data by Application

5.1 Global Vasomotor Symptoms of Menopause Treatment Historic Market Size by Application (2019-2024)

5.2 Global Vasomotor Symptoms of Menopause Treatment Forecasted Market Size by Application (2025-2030)

6 North America

6.1 North America Vasomotor Symptoms of Menopause Treatment Market Size (2019-2030)

6.2 North America Vasomotor Symptoms of Menopause Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030

6.3 North America Vasomotor Symptoms of Menopause Treatment Market Size by Country (2019-2024)

6.4 North America Vasomotor Symptoms of Menopause Treatment Market Size by Country (2025-2030)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Vasomotor Symptoms of Menopause Treatment Market Size (2019-2030)

7.2 Europe Vasomotor Symptoms of Menopause Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030

7.3 Europe Vasomotor Symptoms of Menopause Treatment Market Size by Country (2019-2024)

7.4 Europe Vasomotor Symptoms of Menopause Treatment Market Size by Country (2025-2030)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Vasomotor Symptoms of Menopause Treatment Market Size (2019-2030)

8.2 Asia-Pacific Vasomotor Symptoms of Menopause Treatment Market Growth Rate by Region: 2019 VS 2023 VS 2030

8.3 Asia-Pacific Vasomotor Symptoms of Menopause Treatment Market Size by Region (2019-2024)

8.4 Asia-Pacific Vasomotor Symptoms of Menopause Treatment Market Size by Region (2025-2030)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Vasomotor Symptoms of Menopause Treatment Market Size (2019-2030)

9.2 Latin America Vasomotor Symptoms of Menopause Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030

9.3 Latin America Vasomotor Symptoms of Menopause Treatment Market Size by Country (2019-2024)

9.4 Latin America Vasomotor Symptoms of Menopause Treatment Market Size by Country (2025-2030)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Vasomotor Symptoms of Menopause Treatment Market Size (2019-2030)

10.2 Middle East & Africa Vasomotor Symptoms of Menopause Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030

10.3 Middle East & Africa Vasomotor Symptoms of Menopause Treatment Market Size by Country (2019-2024)

10.4 Middle East & Africa Vasomotor Symptoms of Menopause Treatment Market Size by Country (2025-2030)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Amgen Inc.

11.1.1 Amgen Inc. Company Detail

11.1.2 Amgen Inc. Business Overview

11.1.3 Amgen Inc. Vasomotor Symptoms of Menopause Treatment Introduction

11.1.4 Amgen Inc. Revenue in Vasomotor Symptoms of Menopause Treatment Business (2019-2024)

11.1.5 Amgen Inc. Recent Development

11.2 EndoCeutics, Inc.

11.2.1 EndoCeutics, Inc. Company Detail

11.2.2 EndoCeutics, Inc. Business Overview

11.2.3 EndoCeutics, Inc. Vasomotor Symptoms of Menopause Treatment Introduction

11.2.4 EndoCeutics, Inc. Revenue in Vasomotor Symptoms of Menopause Treatment Business (2019-2024)

11.2.5 EndoCeutics, Inc. Recent Development

11.3 Euroscreen S.A.

11.3.1 Euroscreen S.A. Company Detail

11.3.2 Euroscreen S.A. Business Overview

11.3.3 Euroscreen S.A. Vasomotor Symptoms of Menopause Treatment Introduction

11.3.4 Euroscreen S.A. Revenue in Vasomotor Symptoms of Menopause Treatment Business (2019-2024)

11.3.5 Euroscreen S.A. Recent Development

11.4 MenoGeniX, Inc.

11.4.1 MenoGeniX, Inc. Company Detail

11.4.2 MenoGeniX, Inc. Business Overview

11.4.3 MenoGeniX, Inc. Vasomotor Symptoms of Menopause Treatment Introduction

11.4.4 MenoGeniX, Inc. Revenue in Vasomotor Symptoms of Menopause Treatment Business (2019-2024)

11.4.5 MenoGeniX, Inc. Recent Development

11.5 Mithra Pharmaceuticals S.A.

11.5.1 Mithra Pharmaceuticals S.A. Company Detail

11.5.2 Mithra Pharmaceuticals S.A. Business Overview

11.5.3 Mithra Pharmaceuticals S.A. Vasomotor Symptoms of Menopause Treatment Introduction

11.5.4 Mithra Pharmaceuticals S.A. Revenue in Vasomotor Symptoms of Menopause Treatment Business (2019-2024)

11.5.5 Mithra Pharmaceuticals S.A. Recent Development

11.6 Pherin Pharmaceuticals, Inc.

11.6.1 Pherin Pharmaceuticals, Inc. Company Detail

11.6.2 Pherin Pharmaceuticals, Inc. Business Overview

11.6.3 Pherin Pharmaceuticals, Inc. Vasomotor Symptoms of Menopause Treatment Introduction

11.6.4 Pherin Pharmaceuticals, Inc. Revenue in Vasomotor Symptoms of Menopause Treatment Business (2019-2024)

11.6.5 Pherin Pharmaceuticals, Inc. Recent Development

11.7 Pivot Pharmaceuticals Inc

11.7.1 Pivot Pharmaceuticals Inc Company Detail

11.7.2 Pivot Pharmaceuticals Inc Business Overview

11.7.3 Pivot Pharmaceuticals Inc Vasomotor Symptoms of Menopause Treatment Introduction

11.7.4 Pivot Pharmaceuticals Inc Revenue in Vasomotor Symptoms of Menopause Treatment Business (2019-2024)

11.7.5 Pivot Pharmaceuticals Inc Recent Development

11.8 Radius Health, Inc.

11.8.1 Radius Health, Inc. Company Detail

11.8.2 Radius Health, Inc. Business Overview

11.8.3 Radius Health, Inc. Vasomotor Symptoms of Menopause Treatment Introduction

11.8.4 Radius Health, Inc. Revenue in Vasomotor Symptoms of Menopause Treatment Business (2019-2024)

11.8.5 Radius Health, Inc. Recent Development

11.9 TherapeuticsMD, Inc.

11.9.1 TherapeuticsMD, Inc. Company Detail

11.9.2 TherapeuticsMD, Inc. Business Overview

11.9.3 TherapeuticsMD, Inc. Vasomotor Symptoms of Menopause Treatment Introduction

11.9.4 TherapeuticsMD, Inc. Revenue in Vasomotor Symptoms of Menopause Treatment Business (2019-2024)

11.9.5 TherapeuticsMD, Inc. Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

FEATURED COMPANIES

Mithra Pharmaceuticals S.A.

Pherin Pharmaceuticals Inc

Pivot Pharmaceuticals Inc

Radius Health, Inc.

TherapeuticsMD

List of Tables

Table 1. Global Vasomotor Symptoms of Menopause Treatment Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030

Table 2. Key Players of Estetrol

Table 3. Key Players of Fezolinetant

Table 4. Key Players of FP-101

Table 5. Key Players of HBN-2

Table 6. Key Players of Others

Table 7. Global Vasomotor Symptoms of Menopause Treatment Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030

Table 8. Global Vasomotor Symptoms of Menopause Treatment Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 9. Global Vasomotor Symptoms of Menopause Treatment Market Size by Region (2019-2024) & (US$ Million)

Table 10. Global Vasomotor Symptoms of Menopause Treatment Market Share by Region (2019-2024)

Table 11. Global Vasomotor Symptoms of Menopause Treatment Forecasted Market Size by Region (2025-2030) & (US$ Million)

Table 12. Global Vasomotor Symptoms of Menopause Treatment Market Share by Region (2025-2030)

Table 13. Vasomotor Symptoms of Menopause Treatment Market Trends

Table 14. Vasomotor Symptoms of Menopause Treatment Market Drivers

Table 15. Vasomotor Symptoms of Menopause Treatment Market Challenges

Table 16. Vasomotor Symptoms of Menopause Treatment Market Restraints

Table 17. Global Vasomotor Symptoms of Menopause Treatment Revenue by Players (2019-2024) & (US$ Million)

Table 18. Global Vasomotor Symptoms of Menopause Treatment Market Share by Players (2019-2024)

Table 19. Global Top Vasomotor Symptoms of Menopause Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Vasomotor Symptoms of Menopause Treatment as of 2023)

Table 20. Ranking of Global Top Vasomotor Symptoms of Menopause Treatment Companies by Revenue (US$ Million) in 2023

Table 21. Global 5 Largest Players Market Share by Vasomotor Symptoms of Menopause Treatment Revenue (CR5 and HHI) & (2019-2024)

Table 22. Key Players Headquarters and Area Served

Table 23. Key Players Vasomotor Symptoms of Menopause Treatment Product Solution and Service

Table 24. Date of Enter into Vasomotor Symptoms of Menopause Treatment Market

Table 25. Mergers & Acquisitions, Expansion Plans

Table 26. Global Vasomotor Symptoms of Menopause Treatment Market Size by Type (2019-2024) & (US$ Million)

Table 27. Global Vasomotor Symptoms of Menopause Treatment Revenue Market Share by Type (2019-2024)

Table 28. Global Vasomotor Symptoms of Menopause Treatment Forecasted Market Size by Type (2025-2030) & (US$ Million)

Table 29. Global Vasomotor Symptoms of Menopause Treatment Revenue Market Share by Type (2025-2030)

Table 30. Global Vasomotor Symptoms of Menopause Treatment Market Size by Application (2019-2024) & (US$ Million)

Table 31. Global Vasomotor Symptoms of Menopause Treatment Revenue Market Share by Application (2019-2024)

Table 32. Global Vasomotor Symptoms of Menopause Treatment Forecasted Market Size by Application (2025-2030) & (US$ Million)

Table 33. Global Vasomotor Symptoms of Menopause Treatment Revenue Market Share by Application (2025-2030)

Table 34. North America Vasomotor Symptoms of Menopause Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 35. North America Vasomotor Symptoms of Menopause Treatment Market Size by Country (2019-2024) & (US$ Million)

Table 36. North America Vasomotor Symptoms of Menopause Treatment Market Size by Country (2025-2030) & (US$ Million)

Table 37. Europe Vasomotor Symptoms of Menopause Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 38. Europe Vasomotor Symptoms of Menopause Treatment Market Size by Country (2019-2024) & (US$ Million)

Table 39. Europe Vasomotor Symptoms of Menopause Treatment Market Size by Country (2025-2030) & (US$ Million)

Table 40. Asia-Pacific Vasomotor Symptoms of Menopause Treatment Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030

Table 41. Asia-Pacific Vasomotor Symptoms of Menopause Treatment Market Size by Region (2019-2024) & (US$ Million)

Table 42. Asia-Pacific Vasomotor Symptoms of Menopause Treatment Market Size by Region (2025-2030) & (US$ Million)

Table 43. Latin America Vasomotor Symptoms of Menopause Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 44. Latin America Vasomotor Symptoms of Menopause Treatment Market Size by Country (2019-2024) & (US$ Million)

Table 45. Latin America Vasomotor Symptoms of Menopause Treatment Market Size by Country (2025-2030) & (US$ Million)

Table 46. Middle East & Africa Vasomotor Symptoms of Menopause Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 47. Middle East & Africa Vasomotor Symptoms of Menopause Treatment Market Size by Country (2019-2024) & (US$ Million)

Table 48. Middle East & Africa Vasomotor Symptoms of Menopause Treatment Market Size by Country (2025-2030) & (US$ Million)

Table 49. Amgen Inc. Company Detail

Table 50. Amgen Inc. Business Overview

Table 51. Amgen Inc. Vasomotor Symptoms of Menopause Treatment Product

Table 52. Amgen Inc. Revenue in Vasomotor Symptoms of Menopause Treatment Business (2019-2024) & (US$ Million)

Table 53. Amgen Inc. Recent Development

Table 54. EndoCeutics, Inc. Company Detail

Table 55. EndoCeutics, Inc. Business Overview

Table 56. EndoCeutics, Inc. Vasomotor Symptoms of Menopause Treatment Product

Table 57. EndoCeutics, Inc. Revenue in Vasomotor Symptoms of Menopause Treatment Business (2019-2024) & (US$ Million)

Table 58. EndoCeutics, Inc. Recent Development

Table 59. Euroscreen S.A. Company Detail

Table 60. Euroscreen S.A. Business Overview

Table 61. Euroscreen S.A. Vasomotor Symptoms of Menopause Treatment Product

Table 62. Euroscreen S.A. Revenue in Vasomotor Symptoms of Menopause Treatment Business (2019-2024) & (US$ Million)

Table 63. Euroscreen S.A. Recent Development

Table 64. MenoGeniX, Inc. Company Detail

Table 65. MenoGeniX, Inc. Business Overview

Table 66. MenoGeniX, Inc. Vasomotor Symptoms of Menopause Treatment Product

Table 67. MenoGeniX, Inc. Revenue in Vasomotor Symptoms of Menopause Treatment Business (2019-2024) & (US$ Million)

Table 68. MenoGeniX, Inc. Recent Development

Table 69. Mithra Pharmaceuticals S.A. Company Detail

Table 70. Mithra Pharmaceuticals S.A. Business Overview

Table 71. Mithra Pharmaceuticals S.A. Vasomotor Symptoms of Menopause Treatment Product

Table 72. Mithra Pharmaceuticals S.A. Revenue in Vasomotor Symptoms of Menopause Treatment Business (2019-2024) & (US$ Million)

Table 73. Mithra Pharmaceuticals S.A. Recent Development

Table 74. Pherin Pharmaceuticals, Inc. Company Detail

Table 75. Pherin Pharmaceuticals, Inc. Business Overview

Table 76. Pherin Pharmaceuticals, Inc. Vasomotor Symptoms of Menopause Treatment Product

Table 77. Pherin Pharmaceuticals, Inc. Revenue in Vasomotor Symptoms of Menopause Treatment Business (2019-2024) & (US$ Million)

Table 78. Pherin Pharmaceuticals, Inc. Recent Development

Table 79. Pivot Pharmaceuticals Inc Company Detail

Table 80. Pivot Pharmaceuticals Inc Business Overview

Table 81. Pivot Pharmaceuticals Inc Vasomotor Symptoms of Menopause Treatment Product

Table 82. Pivot Pharmaceuticals Inc Revenue in Vasomotor Symptoms of Menopause Treatment Business (2019-2024) & (US$ Million)

Table 83. Pivot Pharmaceuticals Inc Recent Development

Table 84. Radius Health, Inc. Company Detail

Table 85. Radius Health, Inc. Business Overview

Table 86. Radius Health, Inc. Vasomotor Symptoms of Menopause Treatment Product

Table 87. Radius Health, Inc. Revenue in Vasomotor Symptoms of Menopause Treatment Business (2019-2024) & (US$ Million)

Table 88. Radius Health, Inc. Recent Development

Table 89. TherapeuticsMD, Inc. Company Detail

Table 90. TherapeuticsMD, Inc. Business Overview

Table 91. TherapeuticsMD, Inc. Vasomotor Symptoms of Menopause Treatment Product

Table 92. TherapeuticsMD, Inc. Revenue in Vasomotor Symptoms of Menopause Treatment Business (2019-2024) & (US$ Million)

Table 93. TherapeuticsMD, Inc. Recent Development

Table 94. Research Programs/Design for This Report

Table 95. Key Data Information from Secondary Sources

Table 96. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Vasomotor Symptoms of Menopause Treatment Market Size Comparison by Type (2024-2030) & (US$ Million)

Figure 2. Global Vasomotor Symptoms of Menopause Treatment Market Share by Type: 2023 VS 2030

Figure 3. Estetrol Features

Figure 4. Fezolinetant Features

Figure 5. FP-101 Features

Figure 6. HBN-2 Features

Figure 7. Others Features

Figure 8. Global Vasomotor Symptoms of Menopause Treatment Market Size Comparison by Application (2024-2030) & (US$ Million)

Figure 9. Global Vasomotor Symptoms of Menopause Treatment Market Share by Application: 2023 VS 2030

Figure 10. Hospital Case Studies

Figure 11. Homecare Case Studies

Figure 12. Clinic Case Studies

Figure 13. Vasomotor Symptoms of Menopause Treatment Report Years Considered

Figure 14. Global Vasomotor Symptoms of Menopause Treatment Market Size (US$ Million), Year-over-Year: 2019-2030

Figure 15. Global Vasomotor Symptoms of Menopause Treatment Market Size, (US$ Million), 2019 VS 2023 VS 2030

Figure 16. Global Vasomotor Symptoms of Menopause Treatment Market Share by Region: 2023 VS 2030

Figure 17. Global Vasomotor Symptoms of Menopause Treatment Market Share by Players in 2023

Figure 18. Global Top Vasomotor Symptoms of Menopause Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Vasomotor Symptoms of Menopause Treatment as of 2023)

Figure 19. The Top 10 and 5 Players Market Share by Vasomotor Symptoms of Menopause Treatment Revenue in 2023

Figure 20. North America Vasomotor Symptoms of Menopause Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 21. North America Vasomotor Symptoms of Menopause Treatment Market Share by Country (2019-2030)

Figure 22. United States Vasomotor Symptoms of Menopause Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 23. Canada Vasomotor Symptoms of Menopause Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 24. Europe Vasomotor Symptoms of Menopause Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 25. Europe Vasomotor Symptoms of Menopause Treatment Market Share by Country (2019-2030)

Figure 26. Germany Vasomotor Symptoms of Menopause Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 27. France Vasomotor Symptoms of Menopause Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 28. U.K. Vasomotor Symptoms of Menopause Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 29. Italy Vasomotor Symptoms of Menopause Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 30. Russia Vasomotor Symptoms of Menopause Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 31. Nordic Countries Vasomotor Symptoms of Menopause Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 32. Asia-Pacific Vasomotor Symptoms of Menopause Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 33. Asia-Pacific Vasomotor Symptoms of Menopause Treatment Market Share by Region (2019-2030)

Figure 34. China Vasomotor Symptoms of Menopause Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 35. Japan Vasomotor Symptoms of Menopause Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 36. South Korea Vasomotor Symptoms of Menopause Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 37. Southeast Asia Vasomotor Symptoms of Menopause Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 38. India Vasomotor Symptoms of Menopause Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 39. Australia Vasomotor Symptoms of Menopause Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 40. Latin America Vasomotor Symptoms of Menopause Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 41. Latin America Vasomotor Symptoms of Menopause Treatment Market Share by Country (2019-2030)

Figure 42. Mexico Vasomotor Symptoms of Menopause Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 43. Brazil Vasomotor Symptoms of Menopause Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 44. Middle East & Africa Vasomotor Symptoms of Menopause Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 45. Middle East & Africa Vasomotor Symptoms of Menopause Treatment Market Share by Country (2019-2030)

Figure 46. Turkey Vasomotor Symptoms of Menopause Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 47. Saudi Arabia Vasomotor Symptoms of Menopause Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 48. Amgen Inc. Revenue Growth Rate in Vasomotor Symptoms of Menopause Treatment Business (2019-2024)

Figure 49. EndoCeutics, Inc. Revenue Growth Rate in Vasomotor Symptoms of Menopause Treatment Business (2019-2024)

Figure 50. Euroscreen S.A. Revenue Growth Rate in Vasomotor Symptoms of Menopause Treatment Business (2019-2024)

Figure 51. MenoGeniX, Inc. Revenue Growth Rate in Vasomotor Symptoms of Menopause Treatment Business (2019-2024)

Figure 52. Mithra Pharmaceuticals S.A. Revenue Growth Rate in Vasomotor Symptoms of Menopause Treatment Business (2019-2024)

Figure 53. Pherin Pharmaceuticals, Inc. Revenue Growth Rate in Vasomotor Symptoms of Menopause Treatment Business (2019-2024)

Figure 54. Pivot Pharmaceuticals Inc Revenue Growth Rate in Vasomotor Symptoms of Menopause Treatment Business (2019-2024)

Figure 55. Radius Health, Inc. Revenue Growth Rate in Vasomotor Symptoms of Menopause Treatment Business (2019-2024)

Figure 56. TherapeuticsMD, Inc. Revenue Growth Rate in Vasomotor Symptoms of Menopause Treatment Business (2019-2024)

Figure 57. Bottom-up and Top-down Approaches for This Report

Figure 58. Data Triangulation

Figure 59. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions